Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * The subjects voluntarily joined this study, were able to sign the informed consent form, and had good compliance; * Age ≥ 18 years old (when signing the informed consent form); * ECOG score 0-1 points; * Diagnosed with operable esophageal squamous cell carcinoma through pathological diagnosis (pathological tissue/cytology) and imaging; * The clinical TNM staging is T2-4aNxM0 * Patients assessed to require routine neoadjuvant therapy; * Have not received immunotherapy, chemotherapy, targeted therapy, or radiotherapy in the past; * Expected survival ≥ 12 weeks Exclusion Criteria: * The subjects have any active autoimmune diseases or a history of autoimmune diseases (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis, thyroid dysfunction (hyperthyroidism/hypothyroidism), and the use of drugs cannot maintain thyroid function within the normal range, or patients who have undergone thyroid surgery and require long-term replacement therapy with thyroid hormone and other drugs after surgery); Subjects with vitiligo or complete remission of childhood asthma who do not require any intervention in adulthood may be included; Asthma in which subjects require bronchodilators for medical intervention cannot be included * The subject has previous or concurrent malignant tumors; * Patients who have received systemic anti-tumor therapy in the past; * Individuals who have undergone …